Intervention not reported
fatigue · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher fatigue (high certainty).
1 finding from 1 review
Intervention not reported
gastrointestinal AEs · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher gastrointestinal AEs (high certainty).
1 finding from 1 review
Intervention not reported
infection · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher infection (high certainty).
1 finding from 1 review
Intervention not reported
metabolic AEs · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher metabolic AEs (high certainty).
1 finding from 1 review
Intervention not reported
pain · Women with newly diagnosed epithelial ovarian cancer
The intervention leads to higher pain (high certainty).
1 finding from 1 review
Intervention not reported
Death from all causes · patients with early stage cervical cancer
The intervention probably leads to lower death from all causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention probably leads to lower disease progression (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 4 toxicity3 · patients with early stage cervical cancer
The intervention probably leads to higher grade 4 toxicity3 (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention showed no clear difference in disease progression (low certainty).
1 finding from 1 review
Pain scores during procedure (VAS: 0 to 100) · women undergoing outpatient colposcopy treatment
1 finding from 1 review
Pain scores during procedure (VAS: 0 to 100) · women undergoing outpatient colposcopy treatment
1 finding from 1 review
Pain scores during procedure (VAS: 0 to 100) · women undergoing outpatient colposcopy treatment
1 finding from 1 review
Intervention not reported
Primary cure (remission) · women withe low‐risk GTN
The intervention probably leads to lower primary cure (remission) (moderate certainty).
1 finding from 1 review
Intervention not reported
Failure of first‐line therapy · women withe low‐risk GTN
The intervention probably leads to higher failure of first‐line therapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events (≥ grade 3) · women withe low‐risk GTN
The intervention showed no clear difference in severe adverse events (≥ grade 3) (low certainty).
1 finding from 1 review
Intervention not reported
Nausea · women withe low‐risk GTN
The intervention showed no clear difference in nausea (moderate certainty).
1 finding from 1 review
Intervention not reported
Alopecia · women withe low‐risk GTN
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Progression‐free survival · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes progression‐free survival at 6 months№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
2 findings from 1 review
RR 0.61 [0.22, 1.68]
Studies not reported
Very low
RR 0.65 [0.12, 3.66]
Studies not reported
Very low
Overall survival · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes overall survival compared with treosulfan (very low certainty).
1 finding from 1 review
HR 0.98 [0.58, 1.67]
Studies not reported
Very low
Skin toxicity (alopecia)№ of participants: 73(1 RCT) · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes skin toxicity (alopecia)№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.32 [0.12, 0.91]
Studies not reported
Very low